Alterola Biotech Inc. logo

Alterola Biotech Inc.

Official communications & shareholder information

Shareholder Update

Dear Shareholder

Further to our last update with regard to the sale of Phytanix Bio to Protagenic Therapeutics, Inc., the Directors of Alterola Biotech Inc. wish to update our shareholders on recent developments. We had been working to try and resolve the issues with Protagenic Therapeutics, Inc. since our last update to shareholders.

On October 28, 2025 Protagenic Therapeutics, Inc. filed a lawsuit against the Sellers, seeking amongst other things, to unwind the transaction. The Directors of Alterola / Sellers absolutely refute the allegations and are currently taking legal advice with regard to the appropriate next steps.

For the latest information, please see the 8K filed by Protagenic Therapeutics, Inc. (filed October 31, 2025).

In order to protect the interests of Alterola and EMC2 Capital LLC shareholders, the Directors of Alterola along with EMC2 Capital LLC have filed a Notice of Repurchase (of assets) with Protagenic Therapeutics, Inc. as per the terms of the Share Exchange Agreement dated May 15, 2025. We have also filed a Cash Settlement demand as per the terms of the Share Exchange Agreement dated May 15, 2025.

We will update shareholders again as and when appropriate.

Sincerely,
The Alterola Biotech Inc. Directors

PTIX 8-K (31 Oct 2025)

Shareholder Update

Dear Shareholder,

This communication is to update you on the status of the transaction entered into on 15 May 2025, whereby Alterola Biotech Inc. entered into a share exchange agreement with Protagenic Therapeutics Inc.

We formally announced this in an 8-K filing with the SEC on 30 June 2025 and, to avoid unnecessary expenditure, filed a Form 15-15D to announce we were becoming non-reporting—hence this update.

In essence, following a shareholder vote of Protagenic Therapeutics, Inc. (expected by 1 September 2025), Alterola shareholders would be provided the opportunity to swap their pro rata shareholding in Alterola Biotech, Inc. (ABTI shares) for shares in Protagenic Therapeutics, Inc. (PTIX shares), with ratios determined on a pro rata basis.

Protagenic Therapeutics, Inc. made an announcement via an 8-K on 13 August 2025 which raises serious concerns to the Alterola Biotech Inc. directors. Accordingly, the directors of Alterola Biotech Inc. are taking appropriate advice to ensure we take the most appropriate actions to best serve the interests of our shareholders. We will provide further updates, as appropriate, to keep you informed of the situation.

Sincerely,
The Alterola Biotech Inc. Directors

SEC 8-K (30 Jun 2025) Form 15-15D PTIX 8-K (13 Aug 2025)